Abstract:Purpose:The T-cell-inflamed phenotype correlates with efficacy of immune-checkpoint blockade, whereas non-T-cell-inflamed tumors infrequently benefit. Tumor-intrinsic WNT/β-catenin signaling mediates immune exclusion in melanoma, but association with the non-T-cell-inflamed tumor microenvironment in other tumor types is not well understood.Experimental Design:Using The Cancer Genome Atlas (TCGA), a T-cell-inflamed gene expression signature segregated samples within tumor types. Activation of WNT/β-catenin signaling was inferred using three approaches: somatic mutations or somatic copy number alterations (SCNA) in β-catenin signaling elements including CTNNB1, APC, APC2, AXIN1, and AXIN2; pathway prediction from RNA-sequencing gene expression; and inverse correlation of β-catenin protein levels with the T-cell-inflamed gene expression signature.Results:Across TCGA, 3,137/9,244 (33.9%) tumors were non-T-cell-inflamed, whereas 3,161/9,244 (34.2%) were T-cell-inflamed. Non-T-cell-inflamed tumors demonstrated significantly lower expression of T-cell inflammation genes relative to matched normal tissue, arguing for loss of a natural immune phenotype. Mutations of β-catenin signaling molecules in non-T-cell-inflamed tumors were enriched three-fold relative to T-cell-inflamed tumors. Across 31 tumors, 28 (90%) demonstrated activated β-catenin signaling in the non-T-cell-inflamed subset by at least one method. This included target molecule expression from somatic mutations and/or SCNAs of β-catenin signaling elements (19 tumors, 61%), pathway analysis (14 tumors, 45%), and increased β-catenin protein levels (20 tumors, 65%).Conclusions:Activation of tumor-intrinsic WNT/β-catenin signaling is enriched in non-T-cell-inflamed tumors. These data provide a strong rationale for development of pharmacologic inhibitors of this pathway with the aim of restoring immune cell infiltration and augmenting immunotherapy.See related commentary by Dangaj et al., p. 2943

β-catenin interacts with and inhibits NF-κB in human colon and breast cancer

Mechanisms of Cytoplasmic β-Catenin Accumulation and Its Involvement in Tumorigenic Activities Mediated by Oncogenic Splicing Variant of the Receptor Originated from Nantes Tyrosine Kinase

β-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer.

Β-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells

Wnt/β-catenin Singal Transduction Pathway and Colorectal Cancer

Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer

Intracellular complement C5a/C5aR1 stabilizes β-catenin to promote colorectal tumorigenesis

PI3K is required for the physical interaction and functional inhibition of NF-κB by β-catenin in colorectal cancer cells.

The Roles of Β-Catenin in Immune System

The regulation of β-catenin activity and function in cancer: therapeutic opportunities

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

Oncogenic Function of DACT1 in Colon Cancer Through the Regulation of Β-Catenin.

NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway

NELF and PAF1C complexes are core transcriptional machineries controlling colon cancer stemness

TNFRSF11B activates Wnt/-catenin signaling and promotes gastric cancer progression

Β-Catenin Expression is Altered in Dysplastic and Nondysplastic Aberrant Crypt Foci of Human Colon

Β-Catenin Expression:The Role in Carcinogenesis and Development of Human Breast Cancer

Study on the effect and mechanism of NFKBIA on cervical cancer progress in vitro and in vivo

Multilevel Regulation of Wnt Signaling by Zic2 in Colon Cancer Due to Mutation of Β-Catenin

Loss of FOXN3 in Colon Cancer Activates Beta-Catenin/tcf Signaling and Promotes the Growth and Migration of Cancer Cells.